Humana Inc. (NYSE: HUM) reported second-quarter adjusted earnings of $7.61 per share on revenue of $40.89 billion, beating Wall Street estimates, but shares fell as the insurer announced it plans to exit approximately 600,000 members from lower-return Medicare Advantage plans in 2027. This strategic withdrawal aims to reshape the portfolio toward higher-performing offerings and achieve a sustainable 3% pre-tax margin by 2028, directly impacting member coverage options and profitability metrics.

The company lowered its 2026 GAAP earnings outlook while maintaining its adjusted earnings guidance, citing ongoing pressures in the Medicare Advantage sector. Despite the membership reduction, Humana expects to recapture a significant portion of affected members through other plans, similar to its 2025 efforts. Chief Financial Officer Celeste Mellet stated that the exits are part of a broader strategy including clinical and operating efficiency improvements.

Financial Performance and Membership Trends

Humana’s individual Medicare Advantage membership increased 23% year over year to 6.45 million, with total Medicare membership climbing to 11.13 million. The company continues to expect individual Medicare Advantage membership growth of about 25% in 2026. Medical cost trends remained in line with expectations, with inpatient costs performing better than anticipated.

Strategic Shift and Market Reaction

The planned exits primarily target lower-return plans while preserving benefits for members in higher-performing ones with stronger value-based care penetration. Humana expects to retain just over 40% of affected members, consistent with its 2025 experience. This move comes amid increased regulatory scrutiny on prior authorization practices and a finalized 2.48% increase in Medicare Advantage payment rates for 2027 by the Trump administration.

Humana shares closed Wednesday’s regular trading session down 5.99% at $365.41. The stock was down 1.48% at $360.00 during Thursday’s premarket trading. According to Benzinga Edge Stock Rankings, HUM has a negative short-term price trend, while its medium- and long-term price trends remain positive.

What the Numbers Show

The divergence between strong top-line growth (23% YoY in MA membership) and the decision to shed 600,000 members highlights a strategic pivot from volume to value. While revenue reached $40.89 billion, the focus on achieving a 3% pre-tax margin by 2028 suggests that current profitability levels are below this target. The retention of only 40% of affected members indicates that the remaining 60% may face coverage disruptions or require switching to potentially less favorable plans, underscoring the trade-off between margin expansion and market share stability.

Raymond James analyst John Ransom downgraded Humana (NYSE: HUM) from Outperform to Market Perform, signaling a more cautious stance on the healthcare provider’s equity. The downgrade suggests that analysts expect Humana’s stock to align with broader market movements rather than outperforming peers in the immediate term.

The rating change was issued by Raymond James, a prominent financial services firm, reflecting internal reassessment of Humana’s valuation and growth trajectory. While no specific price target or financial metric was disclosed in the filing, the shift from Outperform implies reduced confidence in near-term upside potential.

Analyst Action Details

Investors typically view a downgrade to Market Perform as a neutral signal, indicating that the stock is expected to move in line with sector or index benchmarks. For Humana, this may reflect concerns over regulatory headwinds, margin pressures, or competitive dynamics within the managed care industry.

What the Numbers Show

Although no quantitative data accompanied the rating change, the decision underscores the importance of analyst sentiment in shaping investor behavior. A downgrade can trigger selling pressure among institutional investors who follow research recommendations closely, potentially impacting short-term trading volume and price stability.

Market participants should monitor subsequent filings or commentary from Raymond James for any updated earnings estimates or strategic insights that may clarify the rationale behind the revised rating.